地诺单抗、骨质疏松症与骨折预防 - Suppr | 超能文献

Denosumab, osteoporosis, and prevention of fractures.

作者信息

Kiechl Stefan, Willeit Johann, Schett Georg

出版信息

N Engl J Med. 2009 Nov 26;361(22):2188-9; author reply 2190-1. doi: 10.1056/NEJMc091893.

DOI:10.1056/NEJMc091893

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Denosumab, osteoporosis, and prevention of fractures.地诺单抗、骨质疏松症与骨折预防

N Engl J Med. 2009 Nov 26;361(22):2188-9; author reply 2190-1. doi: 10.1056/NEJMc091893.

2

Denosumab, osteoporosis, and prevention of fractures.地诺单抗、骨质疏松症与骨折预防

N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.

3

Denosumab (prolia) for postmenopausal osteoporosis.地诺单抗（普丽兰）用于绝经后骨质疏松症。

Med Lett Drugs Ther. 2010 Oct 18;52(1349):81-2.

4

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.地舒单抗对绝经后妇女骨密度和骨转换的影响。

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510.

5

[Denosumab--a new efficient osteoporosis therapy].[地诺单抗——一种新型高效的骨质疏松症治疗方法]

Ugeskr Laeger. 2011 Jan 31;173(5):346-9.

6

Denosumab in postmenopausal women with low bone mineral density.地诺单抗用于绝经后低骨密度女性。

N Engl J Med. 2006 Jun 1;354(22):2390-1; author reply 2390-1. doi: 10.1056/NEJMc060819.

7

Denosumab, osteoporosis, and prevention of fractures.地诺单抗、骨质疏松症与骨折预防

N Engl J Med. 2009 Nov 26;361(22):2189-90; author reply 2190-1.

8

Denosumab, osteoporosis, and prevention of fractures.地诺单抗、骨质疏松症与骨折预防

N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.

9

Study shows that a new type of osteoporosis drug reduces fracture risk.研究表明，一种新型骨质疏松症药物可降低骨折风险。

Harv Womens Health Watch. 2009 Oct;17(2):6-7.

10

Clinical use of denosumab for the treatment for postmenopausal osteoporosis.地舒单抗在绝经后骨质疏松症治疗中的临床应用。

Curr Med Res Opin. 2010 Dec;26(12):2807-12. doi: 10.1185/03007995.2010.533651. Epub 2010 Nov 4.

引用本文的文献

1

Mechanisms of action of therapeutic antibodies for cancer.癌症治疗性抗体的作用机制。

Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23.

2

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study.血清护骨素与一般人群癌症及癌症相关死亡率的未来风险：特罗姆瑟研究。

Eur J Epidemiol. 2015 Mar;30(3):219-30. doi: 10.1007/s10654-014-9975-3. Epub 2014 Dec 2.